Weight gain:: Side effect of atypical neuroleptics?

被引:114
作者
Wetterling, T [1 ]
Müssigbrodt, HE [1 ]
机构
[1] Univ Lubeck, Sch Med, Dept Psychiat, D-2400 Lubeck, Germany
关键词
D O I
10.1097/00004714-199908000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain, To prove whether weight gain is a relevant side effect of atypical neuroleptics, the charts of all patients admitted with DSM-LII-R diagnoses of schizophrenia, schizoaffective disorder, or delusional disorder in the years 1991 to 1995 were evaluated. A retrospective chart review was performed, which included all patients who were treated longer than 2 weeks with a single neuroleptic. The data analysis showed that weight gain must be considered as a common side effect of atypical neuroleptics (clozapine, risperidone, sulpiride, or zotepine). The mean weight gain (3.1, 1.5, 1.9, or 4.3 kg, respectively) was significantly higher than that of patients treated with "classic" neuroleptics (mean, 0.0-0.5 kg) (Kruskal-Wallis, p = 0.01). Young and not obese patients show the highest weight increase. Because weight gain occurs in the first weeks of treatment, particularly in previously untreated subjects, this side effect has to be considered in view of compliance with long-term neuroleptic medication.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 38 条
[1]  
AMIDSEN A, 1964, DAN MED B, V11, P182
[2]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[3]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[4]   INDUCTION OF OBESITY BY PSYCHOTROPIC-DRUGS [J].
BERNSTEIN, JG .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 499 :203-215
[5]   SEROTONIN AND APPETITE [J].
BLUNDELL, JE .
NEUROPHARMACOLOGY, 1984, 23 :1537-1551
[6]  
Bustillo JR, 1996, AM J PSYCHIAT, V153, P817
[7]   DOUBLE-BLIND CONTROLLED-STUDY OF PIPOTHIAZINE PALMITATE IN MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS [J].
CHOUINARD, G ;
ANNABLE, L ;
KROPSKY, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 18 (2-3) :148-154
[8]   RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY [J].
CLAUS, A ;
BOLLEN, J ;
DECUYPER, H ;
ENEMAN, M ;
MALFROID, M ;
PEUSKENS, J ;
HEYLEN, S .
ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) :295-305
[9]  
COHEN S, 1990, AM J PSYCHIAT, V147, P503
[10]   FLUOXETINES EFFECT ON WEIGHT-LOSS IN OBESE SUBJECTS [J].
DARGA, LL ;
CARROLLMICHALS, L ;
BOTSFORD, SJ ;
LUCAS, CP .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 54 (02) :321-325